Public company intelligence preview
NKARTA INC
20 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $2.8M average total compensation across covered insiders.
Governance movement
Public aggregate: 1 governance events in the last year.
Institutional ownership
Public aggregate: 116 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Nkarta Inc. is a Healthcare sector, Biotechnology company focused on clinical-stage allogeneic, off-the-shelf engineered NK cell therapies. Its lead program, NKX019, targets CD19 and is being developed for several B-cell mediated autoimmune diseases, including lupus nephritis, systemic lupus erythematosus, myasthenia gravis, and related indications. The company has also deprioritized earlier oncology efforts, such as NKX101, to concentrate resources on NKX019 and improve the odds of clinical success. Its operations are centered in California and include internal cGMP manufacturing capabilities designed to support scalable, off-the-shelf cell therapy production.
Executive Compensation Practices
As a pre-revenue biotech, Nkarta’s executive compensation is likely to be shaped less by sales growth and more by clinical milestones, regulatory progress, financing discipline, and execution on pipeline prioritization. In this type of Biotechnology business, compensation packages often lean heavily on equity awards and long-term incentives to align management with trial success, platform validation, and eventual value creation, especially when operating losses remain substantial. For Nkarta specifically, progress in NKX019 trials, improvements in conditioning regimens, manufacturing scale-up, and prudent capital management would be logical performance drivers for incentive pay. The company’s workforce reduction and focus on lowering burn suggest that executives may also be evaluated on cost containment and extending cash runway, not just scientific advancement.
Insider Trading Considerations
Insider trading activity in a clinical-stage biotech like Nkarta is often highly sensitive to trial updates, regulatory interactions, manufacturing readiness, and financing needs. Because the company has no product revenue and its valuation can move sharply on data readouts or changes to study design, insiders may face heightened restrictions around trading near clinical announcements, DSMB reviews, or FDA-related milestones. The company’s emphasis on NKX019, the expanded autoimmune trial program, and updates showing deeper B-cell depletion are the kinds of developments that can materially affect sentiment and insider behavior. Investors should also watch for trades around capital raises or periods when management has visibility into cash runway, since funding needs are a major strategic issue for companies in this sector.
Unlock the full NKTX insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.